LivaNova (NASDAQ:LIVN) Announces Quarterly Earnings Results

LivaNova (NASDAQ:LIVN) announced its earnings results on Wednesday. The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.17, FiscalAI reports. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. The company had revenue of $393.15 million for the quarter, compared to analyst estimates of $381.13 million. During the same quarter last year, the company earned $1.11 earnings per share. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year.

Here are the key takeaways from LivaNova’s conference call:

• Broad-based growth led to higher guidance. Third-quarter revenue rose 10% to $393 million, and LivaNova raised its 2026 revenue growth outlook to 9%–10% and adjusted EPS outlook to $4.40–$4.50.
• Cardiopulmonary growth and capacity expansion are supporting further gains. Segment revenue increased 11%, with strength in heart-lung machines and consumables; a new oxygenator line is operational, and the company expects double-digit output growth in 2027.
• Epilepsy momentum strengthened. Revenue grew 11%, supported by higher volume and realized pricing, clinical evidence, and improved reimbursement; LivaNova raised its 2026 epilepsy growth outlook to 8%–9%.
• OSA remains a key future growth opportunity, though commercialization is still ahead. The company cited differentiated clinical results and new category CPT codes expected to take effect in 2028, while planning a limited launch in 2027 and larger commercial investment beginning in 2028.
• Investment and working-capital needs weighed on cash generation. Quarterly adjusted free cash flow fell to $56 million from $62 million a year earlier, while capital spending increased; full-year adjusted free cash flow guidance was maintained at $140 million–$160 million.

LivaNova Price Performance

Shares of NASDAQ:LIVN traded down $3.08 during trading on Thursday, reaching $91.11. 890,211 shares of the company traded hands, compared to its average volume of 745,273. The firm has a market capitalization of $5.02 billion, a PE ratio of 26.96 and a beta of 0.91. LivaNova has a 52 week low of $48.82 and a 52 week high of $99.38. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22. The company’s 50 day moving average is $78.85 and its two-hundred day moving average is $73.25.

More LivaNova News

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q3 2026 revenue rose 9.9% year over year to $393.2 million, ahead of estimates, while adjusted earnings of $1.23 per share topped the roughly $1.06 consensus. LivaNova beats Q3 2026 estimates and raises full-year EPS guidance
• Positive Sentiment: Management raised 2026 adjusted EPS guidance to $4.40–$4.50 and forecast revenue growth of 9%–10%, reinforcing expectations for continued growth. LivaNova forecasts 2026 revenue growth and raises EPS guidance
• Positive Sentiment: Analysts raised targets following the results: Needham increased its target to $112 from $93 and maintained Buy, while Baird raised its target to $111 from $95 and kept Outperform. These revisions suggest analysts see further upside. Needham raises price target
• Positive Sentiment: LivaNova is also exploring entry into obstructive sleep apnea (OSA) neuromodulation, a potential growth opportunity, though this remains a forward-looking development. LivaNova eyes OSA neuromodulation entry
• Neutral Sentiment: Despite the earnings and outlook upgrades, LIVN is pulling back after recent gains. The available reports do not identify a specific negative development behind the retreat, so investors may be weighing the strong results against the stock’s recent rally.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 3,500 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $78.01, for a total transaction of $273,035.00. Following the sale, the director directly owned 4,434 shares in the company, valued at $345,896.34. This represents a 44.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Brooke Story sold 2,300 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the transaction, the director directly owned 7,488 shares in the company, valued at approximately $609,672.96. This represents a 23.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 7,450 shares of company stock worth $591,839 in the last 90 days. 0.35% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Raymond James Financial set a $120.00 price objective on LivaNova in a research report on Wednesday. Needham & Company LLC boosted their target price on shares of LivaNova from $93.00 to $112.00 and gave the company a “buy” rating in a research report on Wednesday. Robert W. Baird upped their price target on shares of LivaNova from $95.00 to $111.00 and gave the company an “outperform” rating in a research note on Thursday. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price target (up from $87.00) on shares of LivaNova in a research report on Wednesday, September 2nd. Finally, Zacks Research lowered shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, LivaNova has an average rating of “Moderate Buy” and an average target price of $99.56.

About LivaNova

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.